<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997801/" ref="ordinalpos=909&amp;ncbi_uid=2621077&amp;link_uid=PMC2997801" image-link="/pmc/articles/PMC2997801/figure/F1/" class="imagepopup">Figure. The main gene abnormalities targeting NF-κB <span class="highlight" style="background-color:">pathway</span> are displayed in red and italic font.  From: Positioning NF-?B in multiple myeloma. </a></div><br /><div class="p4l_captionBody">They result in aberrant activation of non-canonical and canonical NF-κB pathway that together with other signaling pathway activation (JAK/STAT, MAPkinase, PI3K/AKT) trigger myeloma cell survival, proliferation and drug resistance.</div></div>